The Phase 1 trial run in combination with the Royal Melbourne Hospital, the just one in Australia targeting non-genetic bvFTD, and among a handful worldwide, revealed that the drug, salt selenate is safe and well-tolerated in clients with bvFTD over a period of 12 months. Significantly, most of clients receiving salt selenate revealed no modification in their cognitive or behavioral signs, and minimized rates of brain atrophy over the trial period. The arise from the trial, led by Dr. Lucy Vivash, from Monash Universitys Department of Neuroscience, have simply been published in the journal, Alzheimers and Dementia: Translational Research and Clinical Interventions..
In practically half of the cases with bvFTD, the damage to the neurons in the brain is triggered by the accumulation of a protein called tau. This protein is a significant target for research study in the prevention and treatment of Alzheimers and other dementias, as a method to reverse the neurodegeneration triggered by this tau accumulation.
According to Dr. Vivash, salt selenate upregulates an enzyme in the brain that successfully breaks down the tau protein. “We have previously shown, in a Phase 2 trial, that sodium selenate given to patients with moderate to moderate Alzheimers Disease led to less neurodegeneration than in those who did not,” she stated. Notably those patients in the trial with higher levels of selenium, a breakdown item of sodium selenate, in their bloodstream showed less cognitive decrease.
Recommendation: “A phase 1b open-label study of salt selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia” by Lucy Vivash, Charles B. Malpas, Christian Meletis, Meghan Gollant, Dhamidhu Eratne, Qiao-Xin Li, Stuart McDonald, William T. OBrien, Amy Brodtmann, David Darby, Christopher Kyndt, Mark Walterfang, Christopher M. Hovens, Dennis Velakoulis and Terence J. OBrien, 5 May 2022, Alzheimer s & & Dementia Translational Research & & Clinical Interventions.DOI: 10.1002/ trc2.12299.
The research study group is now performing a larger study at lots of healthcare facilities across Australia and New Zealand to further test whether this drug is beneficial for clients with bvFTD. For more information please contact [email secured]
Behavioral alternative frontotemporal dementia (bvFTD) is a rapidly advancing damaging disease and can take place in people as young as 35 years of age. It is characterized by behavioral disruptions and personality modifications and can be highly disruptive and stressful for both clients and their households. Notably, the majority of patients getting sodium selenate showed no modification in their behavioral or cognitive symptoms, and reduced rates of brain atrophy over the trial period.
Monash University researchers have found a possible brand-new treatment for a common type of dementia in under 60s. Salt selenate was shown to stabilize behavioral problems and sluggish brain shrinking in a Phase 1 trial, using wish for clients with behavioral variant frontotemporal dementia.
Sodium selenate slows behavioral alternative frontotemporal dementia, the 2nd most typical dementia in those under 60.
A Monash University-led study has actually found an appealing brand-new treatment for patients with behavioral variant frontotemporal dementia, the 2nd most common kind of dementia in the under 60s– resulting in a supporting of what would usually be intensifying behavioral concerns, and a slowing down of brain shrinkage due to the illness. It is the second scientific trial to reveal that the drug, sodium selenate, may slow cognitive decrease and neurodegenerative damage that is the trademark of numerous dementias including Alzheimers Disease.
Behavioral variant frontotemporal dementia (bvFTD) is a rapidly progressing devastating disease and can occur in individuals as young as 35 years of age. It is defined by behavioral disruptions and personality changes and can be highly disruptive and stressful for both patients and their households. Currently, there are no treatments or cures for bvFTD and normal survival is 5-7 years from medical diagnosis..